1. Tirzepatide: more patients hit weight, blood-pressure and cholesterol targets together

What is new. A post hoc analysis pooling the SURMOUNT 1-4 program examined a clinically intuitive composite: achieving a specified weight-loss threshold, at least a 5 mmHg reduction in systolic blood pressure, and non-HDL cholesterol below 130 mg/dL.

What the study found. Across the trials, 32-38% of tirzepatide-treated participants versus 2-8% of placebo-treated participants reached the composite when the weight-loss threshold was at least 5%. When the threshold was raised to at least 10%, 28-37% versus 1-5% reached it; with at least 15% weight loss, 22-34% versus 1-3% reached it. All reported treatment comparisons were statistically significant.

Why it matters. Obesity treatment should be judged by more than the number on the scale. This analysis highlights the possibility of simultaneous improvement in adiposity, blood pressure and atherogenic lipoprotein burden. It does not, however, prove that this particular composite translates into fewer heart attacks, strokes or deaths; the authors explicitly note that event-based cardiovascular studies in obesity are ongoing.

BELITE clinical perspective. For routine care, the useful takeaway is to track cardiometabolic response alongside weight: blood pressure, lipid profile, glucose status and relevant comorbidities can reveal benefits that a weight-only endpoint misses.

Primary source: Sattar N, et al. PLOS One. Published August 13, 2026. DOI: 10.1371/journal.pone.0345032

2. Three years of tirzepatide and cardiovascular risk: encouraging, but still modeled

What is new. An August 10 post hoc analysis of the three-year SURMOUNT-1 extension used the Framingham Heart Study equation to estimate 10-year cardiovascular disease risk in participants with obesity or overweight and prediabetes who did not have established cardiovascular disease at baseline.

What the study found. Among 962 participants with evaluable risk scores, tirzepatide 15 mg was associated with a 1.92-percentage-point reduction from baseline in predicted 10-year cardiovascular risk at week 72, while placebo was associated with a 1.10-point increase. At week 176, predicted risk remained 1.31 points below baseline with tirzepatide, while placebo was 3.84 points above baseline.

The important limitation. These are risk-model estimates, not observed reductions in heart attacks, strokes or cardiovascular deaths. Even the reported model-derived hazard ratios are approximations from predicted survival, not time-to-event hazard ratios generated from actual cardiovascular outcomes. The authors state that event-based confirmation is still needed, including SURMOUNT-MMO.

BELITE clinical perspective. The result supports the idea that sustained weight loss plus improvements in blood pressure and other risk factors may have durable cardiovascular implications. It should not be presented to patients as proof that tirzepatide has reduced cardiovascular events in this specific primary-prevention obesity population.

Primary source: Sattar N, et al. European Journal of Preventive Cardiology. Published August 10, 2026. DOI: 10.1093/eurjpc/zwag408

3. GLP-1 weight loss and the skin: benefits and tradeoffs show up together

What is new. A patient-reported dermatology study examined skin, hair, facial-volume and strength changes among people using weight-management regimens that included GLP-1 receptor agonists, non-GLP-1 therapies, or combinations.

What the study found. Patients reported improvement in several inflammatory or hormonally influenced skin conditions, including conditions such as psoriasis, eczema, acanthosis nigricans and hirsutism. At the same time, cosmetic and body-composition concerns became more common as weight loss increased. Among respondents reporting more than 20% body-weight loss, 72% reported skin sagging, 52% hair loss, 50% decreased facial volume and 33% reduced strength.

How to interpret it. This was a voluntary, patient-reported observational survey. It can identify patterns and patient concerns, but it cannot establish that GLP-1 receptor agonists directly caused each reported change. Large, rapid weight loss itself can affect facial fat, skin laxity, hair cycling and perceived muscularity.

BELITE clinical perspective. The study reinforces a practical point: treatment quality includes the composition and pace of weight loss, nutrition, protein adequacy and resistance exercise – not simply maximum weight reduction. Dermatologic symptoms that are persistent, severe or unexpected deserve individualized evaluation rather than being dismissed as an inevitable “GLP-1 effect.”

Primary source: Rao S, et al. Dermatology and Therapy. Published August 11, 2026. DOI: 10.1007/s13555-026-01882-z

BELITE BOTTOM LINE

The common theme this week is treatment quality. The strongest obesity-treatment story is increasingly not just how much weight is lost, but whether treatment improves cardiovascular risk factors, preserves function and nutrition, and anticipates consequences of large or rapid weight reduction. The new data are useful, but two of the three studies are post hoc analyses and the dermatology report is observational; none should be overinterpreted beyond its design.